[HTML][HTML] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness and …, 2015 - Springer
Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

[PDF][PDF] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila, M O'Leary - 2015 - cyberleninka.org
Background: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

[PDF][PDF] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila, M O'Leary - 2015 - researchgate.net
Background: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

Cost‑effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness & …, 2015 - search.ebscohost.com
Background: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

[HTML][HTML] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts… - Cost …, 2015 - resource-allocation.biomedcentral …
The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium
monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model …

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness and …, 2015 - search.proquest.com
Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness and …, 2015 - europepmc.org
Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

[HTML][HTML] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness and …, 2015 - ncbi.nlm.nih.gov
Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila, M O'Leary - 2015 - cabidigitallibrary.org
Background: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive …

YS Punekar, G Roberts, A Ismaila… - Cost Effectiveness and …, 2015 - infona.pl
Background The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus
tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific …